Recent news releases
-
Apr 27, 2026 Apotex Announces FDA Approval of Generic Infuvite® Pediatric Injection, Eligible for 180 day CGT Exclusivity (Single Dose Vial) Complementing its Recent Approval of Generic Infuvite Adult Injection
-
Apr 23, 2026 Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses
-
Apr 14, 2026 Apotex Announces FDA Approval of First Generic Infuvite® Adult Injection (Single Dose Vial and Pharmacy Bulk package) with 180 Day CGT Exclusivity for the Pharmacy bulk package in Partnership with Orbicular and Gland Pharma
-
Apr 10, 2026 Apotex Receives First U.S. FDA Tentative Approval for a Generic Version of Ozempic® (Semaglutide Injection) in Partnership with Orbicular
-
Apr 7, 2026 Apotex Strengthens Osteoporosis Care in Canada with Health Canada's Approval of DENOZA™, a Denosumab Biosimilar
-
Mar 30, 2026 Apotex announces leadership changes
-
Mar 25, 2026 Apotex Expands Canadian Ophthalmology Portfolio with Health Canada’s Approval of CLOBIVIS™ (Clobetasol Propionate Ophthalmic Suspension, 0.05%)
-
Feb 5, 2026 Apotex licenses exclusive Canadian rights to testosterone replacement therapy Nebido® from Grünenthal
-
Nov 17, 2025 Apotex donation helps Oak Valley Health respond to urgent capacity needs amid rapid community growth
-
Oct 23, 2025 Apotex Receives Health Canada Approval for LOQTORZI® - The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer